Anavex Life Sciences Corp (AVXL)

[sokol]

Results from the Alzheimer’s trial seems to be pretty far away, but wait! The PDD trial in Spain is a 14 week dementia trial involving 120 patients —34 weeks shorter and 330 fewer patients. We may be getting PDD trial news of results on a rolling basis. In any event, If we receive significantly positive news about dementia and motor skills, we should generate interests for Alzheimer’s, Parkinson's and Rett.

Remember, donepezil was marketed on something like a 3-4 ADAS-Cog point benefit over placebo over about 6 months. If the PDD trial confirms ADAS-Cog benefit demonstrated for 148 weeks and indicates a ADAS-Cog more than a 3-4 point benefit over the placebo, Anavex should generate serious interests.

The PDD trial news, unlike the AD trial news, is not that far away.